| Literature DB >> 14613537 |
Luiz E Henkes1, John S Davis, Bo R Rueda.
Abstract
The corpus luteum is a unique organ, which is transitory in nature. The development, maintenance and regression of the corpus luteum are regulated by endocrine, paracrine and autocrine signaling events. Defining the specific mediators of luteal development, maintenance and regression has been difficult and often perplexing due to the complexity that stems from the variety of cell types that make up the luteal tissue. Moreover, some regulators may serve dual functions as a luteotropic and luteolytic agent depending on the temporal and spatial environment in which they are expressed. As a result, some confusion is present in the interpretation of in vitro and in vivo studies. More recently investigators have utilized mutant mouse models to define the functional significance of specific gene products. The goal of this mini-review is to identify and discuss mutant mouse models that have luteal anomalies, which may provide some clues as to the significance of specific regulators of corpus luteum function.Entities:
Mesh:
Year: 2003 PMID: 14613537 PMCID: PMC293426 DOI: 10.1186/1477-7827-1-87
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Summary of Reproductive Female Phenotypes in Mutant Mice models.
| aCDK2 | Infertile – Follicle arrest with granulosa luteinization; Gigantism with multi tissue hyperplasia and benign adenomas in the pituitary | [ |
| bCDK4 | Impaired postovulatory progesterone secretion and disruption of implantation | [ |
| cp27kip | Ovulation defect; granulosa cells continue to proliferate after luteinization | [ |
| dPDE4D | Infertile – Follicles with entrapped oocytes that undergo luteinization | [ |
| eNrip1 | Infertile – Unruptured follicles; granulosa cells undergo luteinization | [ |
| fCon-37 | Infertile – Mature oocytes fail to ovulate | [ |
| gPRLR | Infertile – Fewer follicles, reduced ovulation, irregular cycles, reduced fertilization rates, defective preimplantation embryo development an lack the ability to initiate pseudopregnancy | [ |
| hPRKO | Infertile – Inability to ovulate, uterine hyperplasia, limited mammary development and inability to exhibit sexual behavior | [ |
| iαERKO | αERKO females are acyclic, infertile and display enlarged, hemorrhagic cystic follicles with a high incidence of ovarian tumors | [ |
| jβERKO | βERKO females are sub fertile, have decreased ovulation rates, fewer litters, less pups and sparse corpora lutea | [ |
| kLHR | Infertile – arrested follicular development at the early antral stage | [ |
| lLats – 1 | Infertile-Growth retardation and lack of mammary development; Most follicles are primary and secondary; No evidence of corpora lutea formation | [ |
| mC/EBPβ | Infertile – Fail to initiate or maintain a pregnancy | [ |
| neNOS | Irregular estrous cycle and reduced ovulation rate | [ |
| oHyt | Infertile – Continuous diestrous | [ |
| pTIMP-1 | Corpora lutea develop/sub-optimal progesterone | [ |
| qFP | No regression of corpora lutea and fail to spontaneusly undergo parturition | [ |
| rCOX-1 | Delayed parturition | [ |
| sCOX-2 | Reduced ovulation rates, reduced fertilization rates, implantation and decidualization defects | [ |
| tlpr | Irregular follicular development/corpora lutea undergo luteolysis at irregular intervals | [ |
| ugld | Irregular follicular development/corpora lutea undergo luteolysis at irregular intervals | [ |
| vTNFR | Increased number of ovulations, irregular estrous cycles, eventually get locked into a diestrous phase | [ |
| wCasp3 | Delayed structural luteal regression, independent of decrease in progesterone | [ |
| xInsl3 | Disrupted cycle length and increased ovarian apoptosis including follicles and corpora lutea | [ |
List of acronyms or abbreviations: aCyclin dependent kinase 2, bCyclin dependent kinase 4, cp27(kip), dType 4 cAMP-specific phosphodiesterase, eNuclear receptor co-repressor Nrip1 (a.k.a. RIP140), fConnexin-37, gProlactin receptor, hProgesterone receptor, iαEstrogen receptor, jβEstrogen receptor, kLuteinizing hormone receptor, lLarge tumor suppressor homolog 1, mCCAAT/enhancer-binding protein β, nEndothelial nitric oxide synthase, oHypothyroid, pTissue inhibitor of metalloproteinase-1, qProstaglandin F2α receptor, rCyclooxygenase-1, sCyclooxygenase-2, tlymphoproliferation, ugeneralized lymphoproliferative disease, vTumor necrosis factor receptor, wCaspase-3, xInsulin-like factor 3